We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · September 23, 2021

Timing and Durability of Erenumab Response in Chronic Migraine



Additional Info

Disclosure statements are available on the authors' profiles:

Timing and durability of response to erenumab in patients with chronic migraine
Headache 2021 Aug 07;[EPub Ahead of Print], SJ Tepper, S Lucas, M Ashina, TJ Schwedt, J Ailani, J Scanlon, J Klatt, DE Chou, A Wang, G Paiva da Silva Lima

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading